神经节苷脂治疗急性脑梗死疗效观察

目的 评估神经节苷脂(GM1)治疗急性脑梗死的临床疗效和安全性.方法 急性脑梗死患者110例随机分为2组,除接受常规治疗外,治疗组加用GM1治疗,60 mg GM1加入250 ml生理盐水中静滴,1次/d,共2周.观察2组治疗前后神经功能缺损程度评分(NIHSS)及日常生活活动量表(Barthel指数)评分、肢体运动功能的变化和不良反应.结果 治疗前后患者NIHSS评分及Barthel指数评分的2组内及治疗后患者NIHSS评分及Barthel指数评分的2组间比较差别具有统计学意义 ( P <0.05).在整个治疗过程中2组均无明显不良反应发生.结论 GM1注射液对急性脑梗死具有显著疗效,并且安全性好.     

银杏二萜内酯葡胺联合单唾液酸四己糖神经节苷脂对急性期脑梗死神经功能的影响

目的探讨银杏二萜内酯葡胺注射液联合单唾液酸四己糖神经节苷脂(GM1)对急性脑梗死(ACI)患者神经功能的影响。方法选取2017-01—2019-03襄阳市第一人民医院神经科收治的103例ACI患者,按随机数字表法分为2组,分别为单用组51例和联用组52例。2组均给予西医常规治疗;单用组给予GM1静滴,80mg/次,1次/d;联用组联用GM1和银杏二萜内酯葡胺注射液,25mg/次,1次/d;2组治疗时间均为14d。观察2组患者治疗前后格拉斯哥昏迷评分(GCS)、美国国立卫生研究院卒中量表(NIHSS)评分、血液流变学指标、Barthel指数的变化。结果与治疗前比较,治疗后联用组NIHSS评分、血液流变学指标均显著降低,GCS评分、Barthel指数均显著升高(均P0.05)。治疗后联用组NIHSS评分、血液流变学指标显著低于单用组(均P0.05),GCS评分、Barthel指数均显著高于单用组(均P0.05)。结论银杏二萜内酯葡胺和GM1联合应用于治疗急性期脑梗死,能够降低血黏度,有效阻止血小板的聚集,减轻细胞的炎症反应和缺血性脑组织损伤,能够促使神经营养相关因子的分泌,抑制氧化应激反应,从而改善患者缺损的神经功能,对修复受损神经功能有重要的临床意义。     

高压氧联合早期康复治疗急性脑梗死的效果观察

目的观察高压氧联合早期康复治疗急性脑梗死的临床效果。方法选取2013-11—2015-01收治的60例急性脑梗死患者,随机分为2组各30例。对照组采用早期康复功能训练治疗,观察组在早期康复治疗的基础上联合应用高压氧治疗。比较2组治疗前后神经功能缺损评分,应用改良Barthel指数(BI)评定日常生活能力的恢复情况。结果 2组神经功能缺损程度及改良BI评分治疗前无显著差异(P0.05)。治疗后2组神经功能缺损程度及BI评分均显著优于术前,但观察组改善幅度显著优于对照组,差异均有统计学意义(P0.05)。结论早期康复联合高压氧治疗急性脑梗死,能有效促进神经功能和日常生活能力的恢复,提高患者生活质量。     

高压氧对脑梗死后神经功能缺损的效果观察

目的 探讨高压氧治疗在改善脑梗死后神经功能缺损中的效果.方法 选取2006-03-2011-03本院收治296例首次脑梗死患者为研究对象,将其随机分为对照组和观察组每组各148例,对照组常规治疗,观察组在对照组基础上加用高压氧治疗,比较2组治疗后1个疗程与2个疗程的NIHSS评分及治疗前后Barthel指数评估结果.结果 观察组治疗后1个疗程与2个疗程的NIHSS评分及Barthel指数评估结果均显著优于对照组,差异均有统计学意义（P＜0.05）.结论 高压氧治疗在改善脑梗死后神经功能缺损中的效果较好,在脑梗死患者康复期的应用价值较高.     

丁苯酞联合康复训练对急性脑梗死的早期疗效观察

【目的】观察丁苯酞联合康复训练治疗急性脑梗死患者的临床疗效。方法 147例急性脑梗死患者随机分为丁苯酞治疗组和常规治疗组。治疗前后均采用NIHSS评分、临床神经功能缺损程度评分标准、FMA及Barthel指数进行评估,观察早期临床疗效。结果丁苯酞治疗组及常规治疗组患者症状均较入院时改善,NISS评分、神经功能缺损评分较入院时降低,FMA评分及Barthel指数较治疗前升高。丁苯酞治疗组各观察指标改善情况均优于常规治疗组,差异有统计学意义(P0.05)。结论丁苯酞联合康复训练的方案与常规治疗方案相比可更好地改善急性脑梗死患者的神经缺损程度,提高患者日常生活质量。     

尤瑞克林联合丹红治疗急性脑梗死的疗效观察

目的 观察尤瑞克林联合丹红注射液治疗急性脑梗死的有效性,为脑梗死急性期的治疗提供临床参考。方法 选择2017-12—2019-12郑州大学第二附属医院收治的120例急性脑梗死患者,实验组及对照组各60例,在脑梗死常规治疗的基础上,对照组应用丹红,实验组在丹红的基础上加用尤瑞克林,比较2组患者在入院后2周及1个月的NIHSS评分及Barthel指数,从而评估其药物有效性。结果 实验组及对照组患者入院后2周及1个月的NIHSS评分Barthel指数比较:(1)入院后2周,2组NIHSS评分分别为(5.33±3.79)分及(6.20±4.68)分,Barthel指数分别为(55.92±19.45)分及(52.58±26.17)分,实验组NIHSS评分稍低于对照组,其Barthel指数稍高于对照组,但其差异无统计学意义(P0.05);(2)入院后1个月,2组NIHSS评分分别为(3.52±2.94)分及(5.17±4.11)分,Barthel指数分别为(67.00±17.33)分及(56.17±25.49)分,实验组NIHSS评分显著低于对照组,Barthel指数显著高于对照组,其差异具有统计学意义(P0.05)。结论 应用尤瑞克林联合丹红注射液治疗14d,可显著改善急性脑梗死患者1个月后的神经功能缺损症状,并提高其日常生活能力。     

急性脑梗死抑郁状态的预后分析

目的 观察急性脑梗死抑郁状态对神经功能恢复、日常生活能力康复的影响.方法 符合急性脑梗死诊断的192例患者.观察前后均进行汉密尔顿抑郁(HAMD)量表评分,美国国立卫生研究院神经功能缺损(NIHSS)量表评分、日常生活能力(Barthel指数)量表评分.结果 192例急性脑梗死患者符合抑郁状态诊断者60例,占31.25%;不符合抑郁状态者132例占68.75%.抑郁状态组入组时NIHSS评分(8.18±2.46),Barthel指数为(53.33±16.46);非抑郁状态组NIHSS评分(8.15±2.48),Barthel指数为(54.51±17.83),两组无统计学差异,P＞0.05.患者病程第90天(研究终点时间)抑郁状态组NIHSS评分(6.97±2.95),Barthel指数(61.83±18.48);非抑郁状态组NIHSS评分(4.78±2.87),Barthel指数(77.12±17.89);两组比较有显著差异,P＜0.01.提示急性脑梗死抑郁状态对NIHSS与Barthel指数产生不良影响.结论 急性脑梗死抑郁状态明显影响患者神经功能与日常生活能力恢复.     

尤瑞克林治疗轻型急性脑梗死临床分析

目的分析尤瑞克林治疗轻型急性脑梗死的临床疗效及安全性。方法选择漳州市第三医院轻型急性脑梗死患者96例,随机分为治疗组48例及对照组48例。对照组常规给予双联抗血小板聚集药、他汀类药物、清除氧自由基剂药物及早期神经康复;治疗组在对照组治疗的基础上给予尤瑞克林。连续治疗14 d后,评价2组临床疗效;观察治疗前后2组NIHSS评分、mRS评分、改良Barthel指数评分,并观察与治疗相关的不良反应。结果治疗组NIHSS评分、mRS评分、改良Barthel指数评分均显著优于对照组(P0.05),且不良反应少。结论尤瑞克林治疗轻型急性脑梗死疗效确切,可显著改善预后,且安全性好。     

曲克芦丁注射液联合胞磷胆碱钠治疗脑梗死的疗效分析

目的分析曲克芦丁注射液联合胞磷胆碱钠治疗脑梗死的效果。方法选取五莲县妇幼保健院治疗的114例脑梗死患者,采用随机数字表法分为观察组及对照组。对照组采取常规治疗,观察组采用曲克芦丁注射液+胞磷胆碱钠治疗。分析临床疗效、神经功能缺损程度、日常生活能力。结果治疗后,与对照组比较,观察组总有效率显著增高(P0.05);治疗前2组NIHSS评分及Barthel指数比较,差异无统计学意义(P0.05);治疗后2组NIHSS评分下降,Barthel指数提升;治疗后2周、1个月及3个月,观察组NIHSS评分显著低于对照组,Barthel指数显著高于对照组,差异均有统计学意义(P0.05)。结论曲克芦丁注射液联合胞磷胆碱钠治疗脑梗死,可有效提升疗效,降低神经功能缺损程度,提高日常生活能力。     

亚低温治疗急性脑梗死的临床研究

目的　观察亚低温治疗急性脑梗死的临床疗效。方法　 63例经头颅CT或MRI证实的急性脑梗死患者被随机分为亚低温治疗组 (3 2例 )和对照组 (3 1例 )。对照组予以常规药物治疗 ,治疗组在常规药物治疗的同时加用亚低温治疗 ,两组患者分别于治疗前和治疗后的不同时点进行神经功能评分和Barthel指数评分。结果　治疗组在第 10、2 0、3 0、60、90d神经功能评分降低 (P <0 0 5 ) ,Barthel指数增加值在治疗后 60d和 90d均显著高于对照组 (P <0 0 5 )。结论　亚低温治疗可以促进急性脑梗死患者的神经功能恢复 ,改善预后 ,亚低温疗法对急性脑梗死是一种安全有效的治疗方法。     

Satisfaction with quality of life varies with temperament types of patients with schizophrenia

We sought to explore the relationships of three temperament factors with domain-specific subjective quality of life (QOL) of patients with schizophrenia. Ninety patients with schizophrenia were evaluated using the Quality of Life Enjoyment and Life Satisfaction Questionnaire, the Tridimensional Personality Questionnaire, the Positive and Negative Syndromes Scale, the Distress Scale for Adverse Symptoms, the Insight and Treatment Attitudes Questionnaire, the Insight Self-Report Scale, and standardized questionnaires for self-reported emotional distress and stress process-related variables. Predictors of domain-specific QOL were identified using multiple regression techniques. Temperament factors explain 6% to 16% of variability in QOL domain scores among patients with schizophrenia after controlling for the remaining variables (emotional distress, social support, self-esteem, avoidance coping, age, side effects, and depression). We found that higher levels of novelty seeking are associated with better general QOL, physical health, and more positive subjective feelings, whereas higher levels of reward dependence are related to better satisfaction from social relationships. Higher levels of harm avoidance are associated with poorer satisfaction with general activities, and medication. Thus, temperament factors, as assessed by the Tridimensional Personality Questionnaire, substantially influence satisfaction with life quality in schizophrenia. Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL.     

Compliance with health regimens of adolescents with epilepsy

The purpose of this paper was to describe the compliance of adolescents with epilepsy and some factors connected to it. Altogether 300 individuals with epilepsy aged 13-17 years were randomly selected from the Finnish Social Insurance Institution's register. Every fifth person on the list was included in the sample. Seventy-seven per cent (n= 232) of the selected adolescents with epilepsy returned a questionnaire sent to them relating to compliance. The data were analysed using the SPSS software. Twenty-two per cent of the adolescents with epilepsy felt that they complied fully with their suggested health regimens, while 44% placed themselves in the category of "satisfactory compliance", and the remaining 34% reported poor compliance. Compliance with their recommended life-style was poorest, while the highest degree of compliance was recorded for medication. Background variables, such as the duration of the disease, exercise, smoking, alcohol-intake and the number of seizures, were statistically significantly related to compliance (P< 0.001). Good motivation, a strong sense of normality, experience of results, subjective outcome, energy and will-power, support from parents, physicians and nurses, and a positive attitude towards to the disease and its treatment, no threat to social and emotional well-being and no fears of complications and no fear of seizures explained good compliance (P< 0.001).     

血管内栓塞治疗未破裂脑动静脉畸形并发癫痫患者的预后分析

目的分析血管内栓塞治疗未破裂脑动静脉畸形(CAVM)并发癫痫患者的预后情况。方法选择2013年3月至2017年6月收治的符合诊断标准的CAVM并发癫痫发作患者49例为研究对象,分析血管内栓塞治疗后患者的临床症状、生活质量(QOLIE-31)改善情况。结果患者经血管内栓塞治疗后,QOLIE-31各项指标(除了药物影响)评分均明显提高,高于治疗前(P0.05);Spetzler-Martin分级与Engel分级的I~II级例数多于治疗前(P0.05),同时Spetzler-Martin分级I~II级生活质量评分(76.04±18.33)分明显高于III~V级的(65.65±16.76)分(P0.05);Engel分级I~II级的生活质量评分(75.25±17.78)分明显高于III~V级的(66.23±13.22)分(P0.05);血管内栓塞比例80%的生活质量总评分(78.37±18.87)分明显高于栓塞比例80%的(64.16±16.92)分(P0.05);术后患者的头疼症状中重度例数明显低于治疗前(P0.01);患者的NIHSS评分和MRS评分均明显低于治疗前,头疼症状的生活质量评分高于治疗前(均P0.05)。结论血管内栓塞能明显改善未破裂脑动静脉畸形并发癫痫患者的头疼症状、癫痫发作情况、神经功能缺损,提高血管内栓塞比例能够提高患者生活质量。     

Treatment of patients with tardive dystonia with olanzapine

Tardive dystonia represents a complication of long-term use of neuroleptics and its treatment is often unsatisfactory. Atypical neuroleptics appear to improve tardive dystonia, and cases of tardive dystonia successfully managed with clozapine have been reported. The aim of this open-label video-blinded study was to evaluate the antidystonic efficacy of olanzapine, a new atypical neuroleptic with a low risk of agranulocytosis, in a group of four patients (one man and three women) with tardive cervical dystonia. They developed severe dystonia after several years of neuroleptic treatment. Extensive laboratory evaluations, as well as neurophysiologic and neuroradiologic investigations, were negative. Olanzapine was started at a dose of 5 mg/d and increased up to 7.5 mg/d. All patients were evaluated at baseline and after 2, 4, 8, and 12 weeks of treatment, using the Toronto Western Spasmodic Torticollis Rating Scale, and videotaped. At the end of the trial, the videotapes were reviewed and scored by a blind observer. A self-rating visual analog scale completed the disability evaluation.A moderate to marked improvement in dystonia was observed in all patients, and significant differences were observed in Toronto Western Spasmodic Torticollis Rating Scale scores and videotape ratings after 8 and 12 weeks of treatment compared with the basal values (p < 0.05). The average percentage of improvement in Toronto Western Spasmodic Torticollis Rating Scale score and visual analog scale was 26.4% and 42.6%, respectively. No serious side effects were reported at the maximum dosage reached (7.5 mg/d). This study warrants a larger controlled study to conclusively demonstrate the efficacy of olanzapine in tardive dystonia.